Theranostics Health

Theralink Using Phosphoproteomics to Guide Treatment in Late-Stage Breast Cancer
Premium

The firm is the latest iteration of the GMU spinout Theranostics Health, which has been working to drive clinical uptake of its technology for over a decade.

Breaking News

Theranostics Health

Theralink Using Phosphoproteomics to Guide Treatment in Late-Stage Breast Cancer
Premium

Diasorin Nabs FDA 510(k) Clearance for Gram-Negative Bloodstream Infection Panel

In Brief This Week: LinusBio, Oxford Nanopore Technologies

BioMérieux Confirms Full-Year Growth Guidance as Q1 Sales Rise 14 Percent

Augurex Wins Health Canada Approval for Autoimmune Condition Test

Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda

Medicare Covering BillionToOne Northstar Select Cancer Liquid Biopsy Test

Theranostics Health

Theralink Using Phosphoproteomics to Guide Treatment in Late-Stage Breast Cancer Premium

Diasorin Nabs FDA 510(k) Clearance for Gram-Negative Bloodstream Infection Panel

In Brief This Week: LinusBio, Oxford Nanopore Technologies

BioMérieux Confirms Full-Year Growth Guidance as Q1 Sales Rise 14 Percent

Augurex Wins Health Canada Approval for Autoimmune Condition Test

Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda

Medicare Covering BillionToOne Northstar Select Cancer Liquid Biopsy Test

Theralink Using Phosphoproteomics to Guide Treatment in Late-Stage Breast Cancer
Premium